Trial
NCT03694197
Long Term Safety Study of PRALUENT
Phase IVTERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Regeneron Pharmaceuticals
Collaborators
Sanofi
Condition
Heterozygous Familial Hypercholesterolemia
Intervention
Praluent
Why stopped
The primary objective (to evaluate the long-term safety of Praluent) was adequately evaluated in other studies.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2021-06-15